Rinvoq ER 30 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26F9V76
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $55,336
Award facts
- Contract value 100% obligated
- $55,336.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $55,336 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) under a firm fixed-price contract with an ultimate completion date of January 9, 2026. This non-competitive delivery order will be performed at the contractor's facility in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used in the treatment of rheumatoid arthritis and other inflammatory conditions, reflecting the breadth of pharmaceutical products supplied through the Defense Logistics Agency's medical procurement programs.
This delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, a $999.999 billion vehicle extended through December 31, 2031, that provides comprehensive pharmaceutical and medical supply support to military healthcare systems globally. AmerisourceBergen Drug Corp serves as a critical vendor within the federal pharmaceutical supply chain, regularly fulfilling orders across multiple therapeutic domains including specialty medications, generic drugs, and medical devices for the Defense Health Agency and other military healthcare programs. The non-set-aside designation indicates this award was made through open and full competition, consistent with the company's established track record of meeting federal procurement requirements.
Quick answers
Who was awarded contract SPE2DR26F9V76?
SPE2DR26F9V76 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26F9V76 worth?
The government has obligated $55,336 on SPE2DR26F9V76.
Is contract SPE2DR26F9V76 an order under another contract?
Yes. SPE2DR26F9V76 is a delivery order under SPE2DR25D3103, an indefinite delivery contract.
Was contract SPE2DR26F9V76 competed?
The extent of competition for SPE2DR26F9V76 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award